Commentary
Video
Author(s):
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Olaparib Elicits Improved OS Rates in Platinum-Sensitive, Germline/Somatic BRCA+ Relapsed Ovarian Cancer
Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies
FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma